Breaking News
February 22, 2019 - In the Spotlight: “The world is your oyster in geriatrics”
February 22, 2019 - Successful testing of multi-organ “human-on-a-chip” could replace animals as test subjects
February 22, 2019 - Analysis of cervical precancer shows decline in two strains of HPV
February 22, 2019 - Sugary stent eases suturing of blood vessels
February 22, 2019 - From surgery to psychiatry: A medical student reevaluates his motivations
February 22, 2019 - Is New App From Feds Your Answer To Navigating Medicare Coverage? Yes And No
February 22, 2019 - New pacemakers powered by heartbeats could reduce need for surgery
February 22, 2019 - The United States records highest drug overdose death rates
February 22, 2019 - Phase 1 data reinforce safety profile of new drug for treating Duchenne muscular dystrophy
February 22, 2019 - Vitamin D supplementation less effective in the presence of obesity, shows study
February 22, 2019 - Sarepta Announces FDA Acceptance of Golodirsen (SRP-4053) New Drug Application for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 53
February 22, 2019 - An institutional effort to reduce the amount of opioids prescribed following lumbar surgery
February 22, 2019 - Failure to take statins leads to higher mortality rates | News Center
February 22, 2019 - New study explains why some patients report phantom sensations after limb amputation
February 22, 2019 - First motor-controlled heart valves implanted by Mainz University Medical Center
February 22, 2019 - Novel preclinical model mimics persistent interneuron loss seen in preterm infants
February 22, 2019 - Global health burden of glaucoma has increased, study reveals
February 22, 2019 - A holistic approach key to minimize treatment complexity in patients with interstitial lung disease
February 22, 2019 - 1 in 10 middle-aged Chinese adults are at high risk for heart disease, finds study
February 22, 2019 - More than half a million breast cancer patient’s lives saved by improvements in treatment
February 22, 2019 - Study finds no evidence that tougher policies prevent teenage cannabis use
February 22, 2019 - New blood test detects genetic disorders in fetuses
February 22, 2019 - Lower Self-Perception Observed in Children With Amblyopia
February 22, 2019 - Up to 15 percent of children have sleep apnea, yet 90 percent go undiagnosed
February 22, 2019 - Rare pulmonary defect prompts parents’ nationwide search for answers | News Center
February 22, 2019 - Lesbian and bisexual women at greater risk of being overweight, study finds
February 22, 2019 - UQ research may explain why vitamin D is essential for brain health
February 22, 2019 - Heart Attacks Rising Among Younger Women
February 22, 2019 - How your smartphone is affecting your relationship
February 22, 2019 - Orthopaedic surgeon receives prestigious award, $10 million grant | News Center
February 22, 2019 - New sepsis test could save thousands of lives
February 22, 2019 - Cervical cancer could be eradicated by 2100
February 21, 2019 - Sustained smoking cessation can lower risk of seropositive RA
February 21, 2019 - Thousands with chronic UTIs are not receiving the treatment they need
February 21, 2019 - Are teens getting high on social media? The surprising study seeking the pot-Instagram link
February 21, 2019 - Stanford expands biobank services | News Center
February 21, 2019 - Scientists identify link between drinking contexts and early onset intoxication among adolescents
February 21, 2019 - Strong social support may reduce cardiovascular disease risk in postmenopausal women
February 21, 2019 - Rapid expansion of interventions could prevent up to 13 million cases of cervical cancer within 50 years
February 21, 2019 - Motif Bio Receives Complete Response Letter From The FDA
February 21, 2019 - Researchers map previously unknown disease in children
February 21, 2019 - A skeptical look at popular diets: Going gluten-free
February 21, 2019 - Podcast: KHN’s ‘What The Health?’ How Safe Are Your Supplements?
February 21, 2019 - Factors associated with increased risk of developing surgical site infections
February 21, 2019 - Anticipatory signals in eye movements can help measure attentive capacity, learning with greater precision
February 21, 2019 - Study explores daily exposure to indoor air pollutants
February 21, 2019 - Evening exercise does not negatively affect sleep, may also reduce hunger
February 21, 2019 - Artificial intelligence technique can be used to identify alcohol misuse in trauma setting
February 21, 2019 - Overweight, obesity in adolescence associated with increased risk of renal cancer later in life
February 21, 2019 - BGU develops new AI platform for monitoring and predicting ALS progression
February 21, 2019 - Researchers discover a new promising target to improve HIV vaccines
February 21, 2019 - Brief Anesthesia in Infancy Does Not Mar Neurodevelopment
February 21, 2019 - Gaming system helps with autism diagnosis
February 21, 2019 - Heart Disease: Six Things Women Should Know
February 21, 2019 - More States Say Doctors Must Offer Overdose Reversal Drug Along With Opioids
February 21, 2019 - Researchers explore case studies focused on industries that kill more people than employed
February 21, 2019 - Only half of GP practice buildings are fit for purpose
February 21, 2019 - Intense exercise, fasting and hormones can enhance waste-protein removal, study shows
February 21, 2019 - Scientists can monitor brain activity to predict epileptic seizures few minutes in advance
February 21, 2019 - Study quantifies hepatic and intestinal mRNA expression of Ugt isoforms in rats
February 21, 2019 - ‘Apple-Shaped’ Body? ‘Pear-Shaped’? Your Genes May Tell
February 21, 2019 - Can we repair the brain? The promise of stem cell technologies for treating Parkinson’s disease
February 21, 2019 - Trump Plan To Beat HIV Hits Rough Road In Rural America
February 21, 2019 - PENTAX Medical introduces new electrosurgical and argon plasma coagulation platforms
February 21, 2019 - Trump plan to beat HIV hits rough road in rural America
February 21, 2019 - Eating blueberries every day could help decrease blood pressure
February 21, 2019 - ‘No Second Chances’ report calls for new measures to combat cardiovascular disease in Australia
February 21, 2019 - Mayo clinic researchers discuss local case studies of leprosy
February 21, 2019 - Scientists demonstrate key role of salt in allergic immune reactions
February 21, 2019 - Experts propose revising the criteria for diagnosis of Parkinson’s disease
February 21, 2019 - The med student and the machine
February 21, 2019 - Hey, Hey! Ho, Ho! Is Striking For School Nurses The Way To Go?
February 21, 2019 - Latest research encourages children to move out and learn through physical activity
February 21, 2019 - Proper oral hygiene and regular visits to dentist can promote heart health
February 21, 2019 - New, versatile technique for remote control of transplanted cells in Parkinson’s
February 21, 2019 - Why melanoma tumors in the brain may be worse?
February 21, 2019 - New project aims to improve lung disease care in Appalachia
February 21, 2019 - Drug increases melanin production in some people with albinism
February 21, 2019 - Over 1 in 3 adults miss the mark on protein, finds study
February 21, 2019 - CymaBay Therapeutics Announces Seladelpar Granted Breakthrough Therapy Designation by the FDA for the Treatment of Primary Biliary Cholangitis
Customizing Genetically Engineered Models for Specific Research Applications

Customizing Genetically Engineered Models for Specific Research Applications

image_pdfDownload PDFimage_print

An interview with Dr. Philip Dubé, discussing the importance of genetically modified models for understanding neurodegenerative diseases, conducted at SfN by Alina Shrourou, BSc.

What challenges do researchers face when developing drugs for the brain?

The first challenge is access to animal models. There are a lot of licensing issues when it comes to using animal models. Furthermore, the development of a very good mouse model does not mean that that is available for drug development.

© vchal/Shutterstock.com

Secondly, choosing the right type of model can be a challenge. A mouse model will recapitulate some aspects of a disease, but not all. The question then becomes how to choose the right one for your specific target of interest. There are limitations to some animal models, and every year new ones are being created. It can be a big challenge then to choose the appropriate model, stay up to date, and always be able to have access to the most cutting-edge model.

At Taconic Biosciences, we want to ensure that we have consistent quality of the animals that we produce, but we’re also looking to identify the next generation of models that will enable people to study specific therapeutic indications in greater detail and with greater fidelity of the human disease.

How do researchers identify which model is most suited to their research applications?

Let’s look at microbiome work as an example. The key thing that you need is a germ-free mouse, because a germ-free mouse is completely devoid of every single microorganism. That is the basic and essential tool for being able to study how microorganisms affect your physiology and your behavior, and it really impacts everything from infectious disease to neuro-biology.

We’re just beginning to understand the link between the microbiome and neuroscience, behavior, learning and development. Taconic is one of the largest and most long-standing providers of germ-free mice and we offer mice with custom microbiomes to meet our customers’ specific research requirements.

Please give an overview of the animal models that Taconic can provide.

Alongside our microbiome and neuroscience portfolio, we also focus a lot of our efforts on immune-oncology research.

Immuno-oncology is using the body’s immune system to fight cancer. Traditionally, when you’ve done these types of studies in animals, you’re taking a human tumor and putting it into an animal that doesn’t have an immune system. This is clearly a problem if you’re trying to study the immune system. Therefore with this in mind, we’ve generated a variety of different types of humanized mice, ranging from genetically humanized, to putting a human immune system in a mouse.

Additionally, we have a very strong inflammatory bowel disease portfolio. In some cases, there’s a lot of overlap between immuno-oncology and other inflammatory diseases. We have a number of models used vitally to support inflammatory bowel diseases, such as Crohn’s disease and colitis. We recently launched a brand new germ-free version of an IL-10 knockout mouse, which has applications for both microbiome and inflammatory bowel disease study.

What therapeutic areas can Taconic Biosciences’ Neuroscience Portfolio support?

We focus on neuro-degeneration in our Neuroscience portfolio, with our two main areas being Alzheimer’s disease and Parkinson’s disease. Within both of those portfolios, we have a lot of the standard models that have been there for 15-20 years, but we also have brand new genetically engineered models.

We work with the Michael J. Fox Foundation, which allows us to use their resources to design and create what is going to be the next model to study Parkinson’s disease. We also have done some work in ALS, as well as some neurocognitive type disorders.  

How does Taconic develop these disease specific models?

Taconic has a custom model generation group called GEMs Design, based in Cologne, Germany. They’ve been the leaders in doing a lot of genetic engineering for the past 20 years. We create many new models specifically for customers, but occasionally we also will create a new model and decide to commercialize it. Sometimes we’ll make it for a specific company and then talk to them and suggest making it available to everyone.

What does Taconic Biosciences hope to provide to the scientific community by being at Neuroscience 2018?

We’re here, for one, to learn what people need. We’re a company that is highly customizable. When researchers say that they need a specific model, we’re going to use that to help guide the types of products that we offer. We’re here to learn from researchers and to help educate people on different types of Alzheimer’s models and neurodegenerative disease models that we can provide.

About Dr. Philip Dubé

Dr. Philip Dubé is Senior Manager, Global Application Science at Taconic Biosciences. He has 16+ years’ experience in rodent model use, completed research fellowships at Vanderbilt University and Children’s Hospital Los Angeles, and served as an Institutional Animal Care and Use Committee member. Dr. Dubé holds a Ph.D. in physiology and an Honor’s B.Sc. in pharmacology from the University of Toronto.

Tagged with:

About author

Related Articles